Comparative Pharmacology
Head-to-head clinical analysis: BRIVARACETAM versus DEPAKOTE CP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVARACETAM versus DEPAKOTE CP.
BRIVARACETAM vs DEPAKOTE CP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
None Documented
None Documented
Clinical Note
moderateBrivaracetam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Brivaracetam."
Clinical Note
moderateBrivaracetam + Fluconazole
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Brivaracetam."